Tenax Therapeutics Inc TENX:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 5:24 PM EDT
3.94quote price arrow up+0.05 (+1.29%)
Volume
396
Close
3.89quote price arrow up+0.14 (+3.73%)
Volume
42,650
52 week range
3.69 - 61.20
Loading...
  • Open3.79
  • Day High3.93
  • Day Low3.76
  • Prev Close3.75
  • 52 Week High61.20
  • 52 Week High Date11/14/23
  • 52 Week Low3.69
  • 52 Week Low Date03/15/24

Key Stats

  • Market Cap6.87M
  • Shares Out1.77M
  • 10 Day Average Volume0.14M
  • Dividend-
  • Dividend Yield-
  • Beta2.25
  • YTD % Change-82.29

KEY STATS

  • Open3.79
  • Day High3.93
  • Day Low3.76
  • Prev Close3.75
  • 52 Week High61.20
  • 52 Week High Date11/14/23
  • 52 Week Low3.69
  • 52 Week Low Date03/15/24
  • Market Cap6.87M
  • Shares Out1.77M
  • 10 Day Average Volume0.14M
  • Dividend-
  • Dividend Yield-
  • Beta2.25
  • YTD % Change-82.29

RATIOS/PROFITABILITY

  • EPS (TTM)-122.31
  • P/E (TTM)-0.03
  • Fwd P/E (NTM)-0.31
  • EBITDA (TTM)-7.443M
  • ROE (TTM)-92.30%
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)1.55%

EVENTS

  • Earnings Date03/28/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Tenax Therapeutics Inc

 

Profile

MORE
Tenax Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The Company's products include TNX-201 (oral enteric coated imatinib) and TNX-103 (oral levosimendan). The Company is developing dosing and a formulation of imatinib mesylate, a kinase inhibitor for the treatment of pulmonary arterial hypertension (PAH)....
Gerald Proehl
Independent Chairman of the Board
Christopher Giordano
President, Chief Executive Officer, Director
Lawrence Hoffman
Interim Chief Financial Officer
Address
101 GLEN LENNOX DRIVE, SUITE 300
Chapel Hill, NC
27517
United States